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1. Introduction 
Several antisera against human erythrocyte glucose 
6-phosphate dehydrogenase (G6PD, type B) have been 
raised in rabbits and used for the characterization of 
genetic variants of this enzyme protein [l-4]. Use of 
the antiG6PD antisera for estimating the specific 
activity of GGPD variants has recently been criticized 
and shown to be inadequate to this purpose [5]. More- 
over, both the specificity and strength of conventional 
antisera are not satisfactory enough to allow a precise 
characterization of G6PD variants associated with 
severe deficiency of activity [6]. 
In an attempt to overcome these limitations, we 
used cell fusion techniques to obtain anti-G6PD anti- 
body-secreting hybridomas [7]. By this approach, a 
number of antibodies directed to human G6PD were 
isolated after fusion of an 8-azaguanine-resistant 
mouse myeloma line with splenocytes from a mouse 
hyperimmunized with G6PD. 
2. Materials and methods 
2 .l . Purification of G6PD from pooled human cry th- 
racy tes 
Homogeneous G6PD (type B) was obtained as in 
[8,9]. Assays of G6PD activity and protein determi- 
nation were done as in [9]. 
Abbreviations: G6PD, glucose 6-phosphate dehydrogenase; 
HAT,hypoxanthine-aminopterine-thymidine;PBS,phosphate- 
buffered saline (pH 7.2) [21]; BSA,bovine serum albumin; 
SDS. sodium dodecyl sulphate; PAGE, polyacrylamide gel 
electrophoresis 
Elsevrer/North-Holland Biomedical Press 
2.2. Immunization and cell hybridization 
A BALB/c mouse was immunized at 20 days inter- 
vals with 4 subcutaneous injections of pure G6PD 
(50 /.rg each) in Freund’s complete adjuvant . Four days 
prior to removal of the spleen, the mouse was given 
an intravenous injection of G6PD (50 /.tg) in 0.1 ml 
0.9% NaCl. Spleen cells (2.5 X 107) and P3 X 63 
Ag8Ul myeloma cells (a generous gift of Dr M. D. 
Scharff) (0.5 X 1 07) were fused with polyethylene 
glycol 1000 as in [lo]. After fusion the cells were 
resuspended in selective growth medium (HAT), in 
Dulbecco’s modified Eagle’s medium with 20% fetal 
calf serum, seeded in 72 wells of Costar plates (cat. 
no. 3524) in 0.5 ml aliquots and cultured at 37°C in a 
humidified 5% COa atmosphere. Fourteen days after 
fusion vigorously growing cell colonies were seen in 
all wells. 
2.3. Screening procedures, cloning and expansion of 
hybridomas 
Supernatants of the cultures were tested for anti- 
G6PD activity by means of two different procedures: 
(a) Direct hemagglutination, using CrCla-treated, 
G6PDcoated sheep erythrocytes, as in [ 111; 
(b) Solid phase binding assay as in [ 121, using 100 1.c1 
aliquots of pure G6PD (100 p/ml PBS) in each 
of the 96 wells of a flexible polyvinyl chloride 
microtitration plate (Microtiter Plates, cat. no. l- 
220-29), which was kept overnight at 25’C. After 
extensive washings with PBS, 100 1.11 of the vari- 
ous culture supernatants were added and left 4 h 
at 25°C. The wells were washed 5 times, then 
lOO/.ll “‘1-1abelled rabbit anti-mouse Ig anti- 
serum (50 000 cpm) were added to each well (see 
below for radioiodination). After 5 washings, the 
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wells were cut with a hot steel wire and counted 
for radioactivity. A supernatant was considered 
positive when the bound radioactivity exceeded 
by at least 4 times the one recorded in a control 
assay in which the supernatant from a P3X63 
culture was used. 
and recorded at 340 nm with a Gilford mod. 2400 
spectrophotometer. 
2.8. Immunoabsorptiorl and analysis of G6PD by poly- 
aclylamide slab gel electrophorcsis (SDS-PAGE) 
Human erythrocytes were washed twice with 
Cells from wells showing anti-G6PD antibody activ- 
ity were cloned in soft agar as in [ 131. Clones were 
selected on the basis of strong positivity, grown to 
mass culture and injected i.p. into BALB/c mice pre- 
treated with Pristane (2,6,10,14-tetramethylpentadec- 
ane). The monoclonal proteins were then purified from 
ascitic fluid as in [ 141 and used as such or, in the case 
of the protein produced by clone G 12.3 (see section 3). 
after coupling to Sepharose 4B (Pharmacia) [6,15]. 
2.4. Radioiodination 
Purified monoclonal proteins and the IgG fraction 
from a rabbit anti-mouse Ig antiserum (prepared as in 
[16]) were radioiodinated using the chloramine T 
procedure [ 171. 
0.15 M KC1 and hemolysates were obtained by hypo- 
tonic lysis with 9 vol. water, followed by centrifuga- 
tion. Lysates were concentrated to 280 mg Hb/ml by 
dialysis under vacuum ag&st PBS. Part of the lysates 
(1.5 ml) was absorbed on 100 ~1 Sepharose-bound 
mouse IgG in order to avoid non-specific retention. 
After incubation for 4 h, both the pre-absorbed lysate 
and a fraction of native, unabsorbed lysate (1 ml) 
were stirred with G 12.3-Sepharose (50 ~1) for 4 h at 
4°C. After extensive washings with PBS, bound G6PD 
was eluted by boiling in 5% (w/v) SDS and the eluates 
were analyzed by SDS-PAGE on gel slabs using the 
Tris system [ 181. A sample of homogeneous G6PD 
which had been stirred sequentially with both immuno- 
absorbents was run in parallel. 
2 5. Class of monoclonal antibodies 
To determine the class of the G 12.3 monoclonal 
antibody, Ouchterlony analysis was performed using 
anticlass, anti-K and anti-h rabbit anti-mouse specific 
antisera (Bionetics). 
3. Results 
3 .l . Screening of positive hybridomas 
2.6. Solid phase binding assay for competitioil experi- 
ments 
This was started in triplicate as above for the 
screening of culture supernatants. Various dilutions 
of ascitic fluids (50 ~1) in 5% (w/v) BSA were added 
to each well together with 50 fi ‘251-labelled G 12.3 
purified antibody (100 000 cpm) diluted in 5% BSA. 
After 4 h at 25”C, the wells were washed 5 times with 
PBS, cut and counted for radioactivity. 
After hybridization, 10 of 72 wells were found 
positive for anti-G6PD activity at the solid phase bind- 
ing assay. Out of these 10 supernatants, two (G 12 and 
G 32) showed marked direct hemagglutination of 
sheep erythrocytes coated with homogeneous human 
G6PD. Cells from the 10 positive wells were cloned in 
soft agar and the resulting clones tested by binding 
assay. Seven clones showing high anti-G6PD antibody 
activity(Gl.6,Gl2.3,Gl4.5,G20.l,G27.5,G32.4 
and G 43.6) were selected, expanded in suspension 
culture and grown as ascites in BALB/c mice for mass 
production of antibodies. 
2.7. Catalytic activity of G6PD in the presence of 3.2. Charactetistics and specificity of G 12.3 antibody 
monoclonal antibodies 
Homogeneous G6PD (100 ng) was preincubated in 
1 ml spectrophotometric cuvettes for 2 h at 25°C 
with varying amounts (10 pg, 1 pg, 100 ng and 25 ng 
total protein) of each of the 7 ascitic fluids in section 3. 
Controls were run in parallel in which the anti-G6PD 
monoclonal antibodies were replaced by identical 
amounts of an ascitic fluid containing mouse IgG or 
IgM myeloma proteins. Reactions were started by addi- 
tion of 0.3 mM NADP and of 2 mM G6P (final cont.) 
The antibody secreted by clone G 12.3 appeared 
immediately to be the most interesting on the basis of 
both hemagglutination titer and affinity of G6PD 
binding. It was therefore chosen for further character- 
ization. Table 1 summarizes the properties of this anti- 
body, classified as IgM K, in comparison with those 
of a conventional rabbit antiserum to G6PD obtained 
and characterized in [4]. 
The Sepharose-bound G 12.3 antibody precipitates 
from erythrocyte lysates of normal subjects a single 
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Table 1 4. Discussion 
Comparative reactivity of monoclonal G 12.3 antibody and 
rabbit antiserum with human G6PD 
- 
Assay system Monoclonal 
G 12.3 anti- 
G6PD (ascites) 
Rabbit anti- 
CXPD (serum) 
~em~~utinationa i:4 x 106b 1:8x 103b 
Binding assaya 1:fOSb l:lOfb 
Radial immuno- 
diffusiona + + 
Ring testC f + 
a See section 2; b absolute dilution; ’ performed as in [ 191 
Monoclonal antibodies produced by hybridomas 
provide a number of advantages over conventional 
antisera: they are obtainable in large amounts and are 
characterized by high titers, by a single defined spe- 
cificity and by remarkable reproducibility of interac- 
tion with the corresponding antigen. ~onoclonal anti- 
bodies to human GGPD provide no exception and 
may represent a tool of considerable analytical poten- 
tial for the following reasons. They may pro~tably be 
used to develop immunohistochemical techniques 
protein ofMr 52 000 which is identical to pure G6PD 
(fig.1). Moreover, this immunoabsorbent failed to 
bind any protein from erythrocyte lysate of a subject 
with complete deficiency of G6PD activity and classi- 
fied as having the Mediterranean variant of GGPD 
(not shown). Both results prove that the G 12.3 anti- 
body is monospecific for human G6PD, while our 
anti-GGPD rabbit antiserum, even after proper absorp- 
tion steps, has been found to interact with several 
erythrocyte proteins. 
3.3. Probing ofantigenic determinants of G6PD by 
way of monoclonal antibodies 
The catalytic activity of purified G6PD is com- 
pletely unaffected by preincubation with each of the 
various ascitic fluids, this suggesting that none of the 
monoclonal antibodies interacts with the catalytic 
sites of the enzyme protein. 
In an attempt to start the immunochemical charac- 
terization of native G6PD, co~n~tition experiments 
were carried out which aimed at clarifying whether or 
not the same determinants on the GGPD molecule are 
recognized by the different monoclonal antibodies. 
Purified G 12.3 antibody was radioiodinated and 
tested in a competitive binding assay. The results in 
table 2 indicate that binding of ra~oiodinated G 12.3 
protein to G6PD is strongly inhibited by the antibody 
secreted by G 32 hybridoma, even at those high dilu- 
tions which obscure the competition afforded by 
unlabelled G 12.3 protein. These patterns suggest 
binding to the same region of G6PD molecule of both 
12.3 and G 32 antibodies, the latter being character- 
ized by a consistently higher affinity. Only limited 
competition is afforded by the G 43.6 ascites at the 
various dilutions, while the other monoclonal anti- 
bodies appear to interact at distinct antigenic sites. 
Fig.1. Immunoabsorption of G6PD from a humanerythrocyte 
lysate by Sepharosecoupled C 12.3 purified antibody. For 
experimental details, see section 2. (1) Purified pre-absorbed 
G6PD; (2) me-absorbed hemolysate; (3) non pm-absorbed 
hemolysate. 
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Table 2 
Inhibition of binding of radioiodinated G 12.3 antibody to human G6PD by 
as&c fluidsa 
Ascites Dilution of ascites in 551 (w/v) BSA 
1:lO 1:lOO 1:lOOO 1:2000 
ig G2b (MPC-1 l)b 0 0 0 0 
G 1.6 0 0 0 0 
G 12.3 94.6 15.4 36.9 7.3 
G 14.5 19.4 0 2.1 9.1 
G 20.1 28.9 6.3 0 0 
G 21.5 37.8 6.1 0 0 
G 32.4c 9.2 2.2 2.6 3.6 
G 43.6 22.3 15.2 19.7 22.0 
G 32 97 91.5 61.8 100 
a Experiments were performed in triplicate as in section 3. Results were expressed 
as % of inhibition and equated to: 
100 - 
cpm bound in the presence of ascites from hybridomas 
x 100 
cpm bound in the presence of control ascites (IgG2b) 
b MPC-11 mouse myeloma cell line [ 131; c The difference between inhibitions by 
uncloned G 32 and clone G 32.4, respectively, may be due to substantial changes 
undergone by the protein (identified as IgM) upon culturing, e.g., the disappear- 
ance of J chain: this view is supported by loss of hemagglutination and retention 
of binding capacity in the clone (see text) 
aimed at localizing this commonly used marker of the 
X chromosome in a number of human cell types and 
of somatic cell hybrids between humans and other 
species. They may be also used for discriminating 
among G6PD-positive and G6PD-negative cells, a situ- 
tion which is typical of the heterozygous condition of 
G6PD deficiency and raises difficult diagnostic prob- 
lems [20]. The product of clone G 12.3 and probably 
the other monoclonal antibodies described here because 
of their specificity toward different determinants on 
the G6PD molecule (table 2), appear to be useful 
probes for topological studies: these can be performed 
on the native G6PD molecule, on eventual discrete 
species arising from post-translational changes (e.g., 
by intracellular proteolysis) and on structural variants 
of this enzyme protein. Another application which 
can be envisioned for monospecific anti-G6PD anti- 
bodies is their use for selective immunoprecipitation 
of ribosome-bound nascent G6PD and for subsequent 
investigations on the molecular organization of the 
G6PD gene in the human X chromosome by means of 
specific mRNA and cDNA probes. 
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